N-PORT filing recap · January 2026

What did ARK Genomic Revolution ETF buy in January 2026?

Reported stock-position changes between this filing and the previous one. These are ARK Genomic Revolution ETF's own holdings, not the firm's.

Stock value

$1.27B

Positions

Estimated turnover

13.7%

Turnover is a proxy: verified trade-origin share changes valued at period-end and divided by average reported stock value. SEC holdings reports do not disclose execution dates or prices. Corporate actions and unreconciled activity are excluded.

Period in review

ARK Genomic Revolution ETF opened a new position in Ataibeckley Inc. and exited Exact Sciences Corporation and Regeneron Pharmaceuticals. It added to Tempus Ai, Crispr Therapeutics, and Beam Therapeutics, while trimming Natera, Adaptive Biotechnologies, and Ionis Pharmaceuticals. The fund also substantially increased its stakes in Genedx Holdings and Caris Life Sciences.

New positions

ATAIAtaibeckley Inc.$12.41Mreported value+3.30M shares

Increased positions

TEMTempus Ai, Inc.$105.01Mreported value+270.0K shares+18.2%CRSPCrispr Therapeutics AG$101.65Mreported value+241.2K shares+13.4%TWSTTwist Bioscience Corporation$91.55Mreported value+122.1K shares+5.8%PSNLPersonalis, Inc.$78.04Mreported value+396.3K shares

Reduced positions

GHGuardant Health, Inc.$76.12Mreported value-26.1K shares-3.8%NTRANatera, Inc.$54.67Mreported value-41.8K shares-15.0%CDNACaredx, Inc.$43.70Mreported value-12.7K shares-0.6%VCYTVeracyte, Inc.$41.79Mreported value-34.9K shares

Exited positions

EXASExact Sciences Corporation$22.00Mprior reported value-340.0K shares-100.0%ATAIAtaibeckley Inc.$17.75Mprior reported value-3.04M shares-100.0%REGNRegeneron Pharmaceuticals, Inc.$7.99Mprior reported value-12.3K shares-100.0%